The 14 Billion Dose COVID-19 Manufacturing Challenge
mRNA Vaccines Leading The Way
Executive Summary
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
You may also be interested in...
Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal
AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.
Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.